Understanding Bone Metabolism and Its Connection to Mood Disorders

The Dynamic Nature of Bone Structure

The human skeletal system is continuously undergoing changes, characterized by a process known as bone metabolism. This dynamic process involves the breakdown and rebuilding of bones, regulated by the brain. Recent research has established a link between mood disorders, such as depression, and bone abnormalities.

Bone Metabolism Disorders in Space

One key area of research focuses on astronauts who experience bone metabolism disorders due to exposure to low gravity environments. Studies have shown that the absence of Earth’s gravitational force leads to a decrease in bone formation, with effects that can persist even after returning to normal gravity.

New Research on Bone Density and Anxiety

Study Overview

A recent study published in the *Journal of Clinical Investigation* investigates the relationship between chronic stress and bone metabolism. The research simulated spaceflight conditions during the 180-day Controlled Ecological Life Support System (CELLS) project, involving three male and one female participant.

Findings from the CELLS Project

At the conclusion of the 180-day simulation, participants exhibited reduced bone density alongside increased self-reported anxiety levels. This increase in anxiety was corroborated by elevated stress hormone levels, including epinephrine, suggesting a potential causal link between anxiety and bone density loss.

Mouse Model Experiments

To delve deeper into the underlying mechanisms, the research team utilized a mouse model. Mice were subjected to chronic mild stress to replicate the stress levels experienced by human participants. Over an eight-week period, these stressed mice displayed significantly lower bone density compared to a control group, mirroring the human results.

Exploring Neural Pathways

The Role of the Hypothalamus

The hypothalamus, known as the “control center” of the brain, regulates various bodily functions, including emotion and bone metabolism. The ventromedial region of the hypothalamus (VMH) is particularly crucial in this regulation. Stress-exposed mice showed elevated levels of gamma-aminobutyric acid (GABA) in the VMH, indicating a role for GABA-ergic neural circuits in bone density loss.

Activation of GABA-ergic Circuits

To further explore this relationship, genetically altered mice with controllable GABA-ergic circuits were used. Stimulating these circuits resulted in increased GABA levels in the VMH, reduced bone density, and heightened anxiety-related behaviors.

Impact of CART Levels

The study also revealed decreased levels of CART (cocaine and amphetamine regulated transcript) in stressed mice. CART is a neurotransmitter that regulates bone resorption, and lower levels are linked to increased bone loss.

Identifying Regulatory Pathways

The research team identified the bed nucleus of stria terminalis (BNST) as the origin of GABA-ergic responses in the VMH. The BNST is associated with stress and anxiety and activates specific somatostatin neurons that project to the VMH. Additionally, the nucleus tractus solitarius (NTS) was found to respond to stress-induced GABA activity from the VMH, establishing a regulatory pathway of BNST-VMH-NTS.

Implications of the Study

The findings of this study are significant for two primary reasons. First, they enhance our understanding of the mechanisms leading to bone density loss and the associated risks of anxiety and stress. Second, by identifying specific pathways and neurotransmitters involved, the research opens potential avenues for targeted therapies addressing bone density issues.

Conclusion

This study highlights the intricate relationship between chronic stress, anxiety, and bone health, paving the way for future research and therapeutic interventions aimed at mitigating bone density loss.

Written by Michael McCarthy.

1. Yang F, Liu Y, Chen S, Dai Z, Yang D, Gao D, et al. A GABAergic neural circuit in the ventromedial hypothalamus mediates chronic stress-induced bone loss. *The Journal of Clinical Investigation*. 2020.